You, Benoit http://orcid.org/0000-0002-3177-8857
Van Wagensveld, Lilian
Tod, Michel
Sonke, Gabe S.
Horlings, Hugo M. http://orcid.org/0000-0003-4782-8828
Kruitwagen, R. F. P. M.
Du Bois, Andreas
Selle, Frédéric
Perren, Timothy
Pfisterer, Jacobus
Joly, Florence
Cook, Adrian
Kaminsky, Marie Christine
Wollschlaeger, Kerstin
Lortholary, Alain
Tome, Oliver
Leary, Alexandra
Freyer, Gilles
Van Der Aa, Maaike
Colomban, Olivier http://orcid.org/0000-0003-1671-3470
Article History
Received: 11 October 2021
Revised: 22 December 2021
Accepted: 1 February 2022
First Online: 31 March 2022
Ethics approval and consent to participate
: All assessed studies (AGO-OVAR 7, AGO-OVAR 9, ICON-7 and NCR) were conducted in accordance with the Declaration of Helsinki ethical guidelines. All patients recruited in the study signed an informed written consent.
: Not applicable.
: AdB: Honoraria/Institutional Grants for Advisory Boards and/or educational activities (last 3 years): Roche; AstraZeneca/MSD; GSK/Tesaro; Clovis; Pfizer; Biocad; Genmab/Seattle Genetics; AMGEN; Zodiac; Founder/Chairman/Executive Board AGO Study Group; Co-Founder, Strategic Board and past president ENGOT; Past Chairman, Scientific Committee, and faculty of consensus conferences GCIG and ESGO/ESMO; Past/Present member national guideline committees Breast- and Ovarian Cancer, and multiple further; Committees, working groups, and editorial boards (eg. J Clin Oncol, Gynecol Oncol, Int J Gynecol Cancer); GSS: GSS reports institutional research support from AstraZeneca, Biovica, Merck, Novartis, Roche and Seagen. BY: consulting for MSD, AstraZeneca, GSK-TESARO, BAYER, Roche-Genentech, ECS Progastrine, Novartis, LEK, Amgen, Clovis Oncology, Merck Serono, BMS, SEAGEN, Myriad. The other authors declare no competing interests that might have impacted the results of this study.